Search for Clinical Trial Results

Sponsored By

Adenosquamous Carcinoma of the Endometrium - 13 Studies Found

Status Study
Completed Study Name: Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Condition:
  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma<
    Date: 2009-11-10
    Interventions:
    • Other: Diagnostic Laboratory Biomarker Analysis

Completed Study Name: Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
Condition:
  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma<
    Date: 2009-01-09
    Interventions: Drug: Gemcitabine Hydrochloride Given IV Other Names
Active, not recruiting Study Name: Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
Condition:
  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma<
    Date: 2012-07-15
    Interventions:
    • Biological: Dalantercept Given
Active, not recruiting Study Name: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Condition:
  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma<
    Date: 2011-03-01
    Interventions:
    • Drug: Akt Inhibitor MK2206 Giv
Completed Study Name: Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Condition:
  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma<
    Date: 2010-05-27
    Interventions:
    • Drug: Cediranib Maleate Given

Recruiting Study Name: Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Condition:
  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma<
    Date: 2007-06-25
    Interventions:
    • Radiation: 3-Dimensional Conformal Radiation Therapy

Completed Study Name: Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Condition:
  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma<
    Date: 2000-07-05
    Interventions:
    • Drug: Doxorubicin Hydrochloride

Recruiting Study Name: Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Condition:
  • Endometrial Adenosquamous Carcinoma
  • Endometrial Clear Cell Aden
    Date: 2013-09-03
    Interventions:
    • Drug: Cabozantinib S-malate Gi
Active, not recruiting Study Name: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
Condition:
  • Endometrial Adenosquamous Carcinoma
  • Endometrial Clear Cell Aden
    Date: 2007-12-15
    Interventions:
    • Drug: Cisplatin Given IV or IP
Active, not recruiting Study Name: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Condition:
  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma<
    Date: 2011-09-24
    Interventions:
    • Drug: Carboplatin Given IV
Next >>>